This site is intended for healthcare professionals in United Arab Emirates

Search

Menu

Close

Sign InLog Out Our MedicinesTherapy AreasExplore ContentExplore ContentDownloadable materials
VideosLet's ConnectLet's ConnectContact usPfizer medical information

Adverse event reporting can be found at the bottom of the page

Menu

Close

MOA MOA MOA EfficacyEfficacyPALOMA-2 Study designPatient Characteristics Primary endpoint Secondary end point PALOMA-3Study design Patient Characteristics Primary endpoint Secondary end point SurvivalFinal analysis Subgroup analysis Prespecified groups Updated Subgroup analysis Safety Safety PALOMA pooled analysis Adverse reactions  & Laboratory abnormalities PALOMA 2 Adverse Events PALOMA 3 Adverse Events IBRANCE consistent  safety profile Pooled analysis of patients aged ≥65 years in the PALOMA trials No evidence of cumulative or delayed toxicity with up to 50 months Patients with visceral diseases GI ,  Liver toxicities, and QTC Dosing Dosing Once daily dosing Dose Modification Real-World EvidenceReal-world EvidenceIBRANCE is the only CDK4/6 inhibitor with >5 years of real-world experience Real-world data provide additional information Favorable progression free rates IRIS Study In the real world, IBRANCE benefits GuidelinesGuidelinesNCCN Guidelines ESMO Guidelines Support & Services Support & Resources Patient support program/tools Events Materials Videos
Ibrance®  US Prescribing Information  Click Here
IBRANCE + letrozole/fulvestrant is recommended by international guidelines as a treatment option for HR+/HER2- mBC1,2
AI= aromatase inhibitor; CDK = cyclin-dependent kinase; FUL= - Fulvestrant; HER2- = human epidermal growth factor receptor 2-negative; HR+ = hormone receptor-positive; LHRH = luteinising hormone-releasing hormone;
mBC = metastatic breast cancer; NCCN = National Comprehensive Cancer Network.

References: 1. National Comprehensive Cancer Network. Clinical practice guidelines in Oncology. Breast Cancer Version 4.2023 — March 23, 2023. NCCN Web site breast.pdf (nccn.org)  Accessed August 2023. 2. Cardoso F, et al. Ann Oncol. 2018;29(8):1634-1657.
IBRANCE + letrozole/fulvestrant is recommended by international guidelines as a treatment option for HR+/HER2- mBC1,2
ABC4 = Fourth International Advanced Breast Cancer Consensus Conference; AI= aromatase inhibitor; CDK = cyclin-dependent kinase; ESO = European School of Oncology; ESMO = European Society for Medical Oncology; ET = endocrine therapy; FUL= - Fulvestrant; HER2- = human epidermal growth factor receptor 2-negative; HR+ = hormone receptor-positive; LHRH = luteinising hormone-releasing
hormone; mBC = metastatic breast cancer.

References: National Comprehensive Cancer Network. Clinical practice guidelines in Oncology. Breast Cancer version 4. 2023 - March 23, 2023. NCCN Web site. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed August 2023. 2. Cardoso F, et al. Ann Oncol. 2018;29(8):1634-1657.

Prescribing Information: Master GULF LEVANT-LPD- (Ibrance)- Capsules- 75 mg, 100 mg &125 mg based on USPI Revision date: December 2022 – United Arab Emirates

PP-IBR-ARE-0144

Report Adverse Events 

If you'd like to report an adverse event related to a Pfizer Product from Gulf (UAE, Bahrain, Qatar, Oman and Kuwait), please send an email with the adverse event details to: [email protected]

Pfizerpro accountPfizerPro Account

Access Pfizer materials, resources and receive communications from Pfizer about our products with a Pfizerpro account.

Sign inRegisterAccountSign Out

Copyright © 2023 Pfizer Gulf FZ LLC. All rights reserved.

 

i- The product information provided in this site is intended only for Healthcare Professionals of UAE. The products discussed herein may have different product labeling in different countries.

 

ii- The information provided on this website is intended only for healthcare professionals of UAE.
 

PP-UNP-BHR-0180